Norepinephrine, a potent α-adrenergic and β-adrenergic agonist, has become a cornerstone in managing hemodynamic instability during anesthesia. Maintaining blood pressure within a safe range during a procedure is essential for improving patient outcomes. Anesthetic drugs, blood loss during surgery, and other perioperative factors can negatively affect hemodynamics. Norepinephrine is one of several drugs that are commonly used to manage these effects.
Norepinephrine exerts its effects primarily by binding to α1-adrenergic and β1-adrenergic receptors. Activation of α1 receptors triggers G-protein-coupled pathways, leading to phospholipase C activation, which increases intracellular calcium and causes vasoconstriction. Simultaneously, β1 receptor stimulation enhances cardiac contractility and heart rate through cAMP-mediated signaling. This dual action increases systemic vascular resistance and maintains cardiac output, making it effective in managing hypotension and shock. At higher doses, α1 effects dominate, while lower doses favor β1-mediated cardiac stimulation. Its applications span critical care, intraoperative settings, and obstetric anesthesia, supported by evolving evidence from clinical trials and meta-analyses.
In septic shock and critical care, norepinephrine is the first-line vasopressor, as endorsed by international guidelines. It corrects hypotension by increasing systemic vascular resistance while maintaining cardiac output through mild β-adrenergic activity. A network meta-analysis highlighted that combining norepinephrine with dobutamine reduces mortality risk in septic shock compared to other agents. This dual mechanism makes it preferable to pure α-agonists like phenylephrine, particularly in distributive shock scenarios where balanced vasoconstriction and cardiac output preservation are critical.
During anesthesia and surgery, norepinephrine has seen increased usage in treating hypotension. A recent multicenter trial involving over 3,600 patients compared norepinephrine and phenylephrine during noncardiac surgery. Compliance with assigned vasopressors exceeded 88%, demonstrating practical feasibility. While 30-day mortality and acute kidney injury rates were similar between groups, norepinephrine’s β-agonist effects may offer theoretical advantages in preserving cardiac output. Larger trials are needed to confirm long-term outcome benefits, but current evidence supports its utility in stabilizing blood pressure without compromising cardiac function.
In obstetric anesthesia, spinal anesthesia for cesarean delivery frequently causes hypotension, posing risks to both maternal and fetal health. Prophylactic norepinephrine infusions have been shown to significantly reduce the incidence of hypotension and severe hypotension compared to reactive administration. However, this approach increases the risk of reactive hypertension, necessitating careful dose optimization. Studies recommend initiating infusions at 0.05–0.075 μg/kg/min, with higher rates balancing efficacy and hypertension risk. Norepinephrine’s potency is approximately 13-fold greater than phenylephrine, allowing for lower doses to achieve equivalent blood pressure control while minimizing adverse effects like bradycardia.
Comparative studies between norepinephrine and phenylephrine reveal distinct hemodynamic profiles. Norepinephrine causes smaller reductions in stroke volume and arterial compliance, attributed to its mixed α/β-agonist activity. In obstetric patients, it is associated with less bradycardia and better maintenance of cardiac output, making it a preferred choice in settings where maternal hemodynamic stability is paramount. These advantages underscore the importance of selecting vasopressors based on patient-specific pathophysiology rather than a one-size-fits-all approach.
Emerging research explores norepinephrine’s impact on coagulation, particularly in hypercoagulable populations such as obstetric patients. An ongoing clinical trial is comparing norepinephrine and phenylephrine effects on prothrombotic markers, including fibrinogen and D-dimer levels, during cesarean sections. Results from this study may refine vasopressor selection in scenarios where thrombosis risk is elevated, adding another layer to personalized anesthetic management.
Norepinephrine’s versatility in treating hypotension is well supported by clinical evidence, and its ability to preserve cardiac output and adapt to diverse clinical scenarios—from septic shock to cesarean delivery—makes it a valuable tool in modern anesthesia. While it outperforms phenylephrine in mitigating cardiac depression, careful dose titration remains essential to avoid reactive hypertension. Ongoing investigations into its prothrombotic potential and long-term outcomes will further clarify its role in optimizing perioperative care.
References
- Tao W, Xie Y, Ding W, Bao J, Zhang Y, Hu X. Effect of norepinephrine and phenylephrine on prothrombotic response in patients undergoing cesarean section under spinal anesthesia: protocol for a randomized, double-blind, controlled study. Trials. 2024 Jul 2;25(1):432. doi: 10.1186/s13063-024-08255-x. PMID: 38956697; PMCID: PMC11218124.
- Khatoon F, Kocarev M, Fernando R, Naz A, Khalid F, Ibrahim Abdalla EO, Columb M. Optimal Infusion Rate of Norepinephrine for Prevention of Spinal Hypotension for Cesarean Delivery: A Randomized Controlled Trial, Using Up-Down Sequential Allocation. Anesth Analg. 2024 Oct 9. doi: 10.1213/ANE.0000000000007231. Epub ahead of print. PMID: 39383097.
- Chen Y, Zou L, Li Z, Guo L, Xue W, He L, Ma S, Ni X. Prophylactic norepinephrine infusion for postspinal anesthesia hypotension in patients undergoing cesarean section: A randomized, controlled, dose-finding trial. Pharmacotherapy. 2021 Apr;41(4):370-378. doi: 10.1002/phar.2514. Epub 2021 Mar 5. PMID: 33583066.
- Guo L, Xu X, Qin R, Shi Y, Xue W, He L, Ma S, Chen Y. Prophylactic Norepinephrine and Phenylephrine Boluses to Prevent Postspinal Anesthesia Hypotension During Cesarean Section: A Randomized Sequential Allocation Dose-Finding Study. Drug Des Devel Ther. 2023 May 23;17:1547-1555. doi: 10.2147/DDDT.S406671. PMID: 37249928; PMCID: PMC10224683.
- Onwochei DN, Ngan Kee WD, Fung L, Downey K, Ye XY, Carvalho JCA. Norepinephrine Intermittent Intravenous Boluses to Prevent Hypotension During Spinal Anesthesia for Cesarean Delivery: A Sequential Allocation Dose-Finding Study. Anesth Analg. 2017 Jul;125(1):212-218. doi: 10.1213/ANE.0000000000001846. PMID: 28248702.